Targeting BCR-ABL and JAK2 in Ph+ ALL

In this issue of Blood, Appelmann et al provide evidence for prolonged survival and prevention of resistance in a mouse model of Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) by combined targeting of the BCR-ABL kinase and Janus kinase 2 (JAK2) with dasatinib and ruxolitinib, respectively. © 2015 by The American Society of Hematology.


Published in:
Blood, 125, 9, 1362-3
Year:
2015
ISSN:
1528-0020
Other identifiers:
Laboratories:




 Record created 2015-03-09, last modified 2018-09-13


Rate this document:

Rate this document:
1
2
3
 
(Not yet reviewed)